← Back to Search

Monoclonal Antibodies

A Study of LY3462817 in Participants With Rheumatoid Arthritis

Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 12

Summary

This trial is testing a new medication called LY3462817 to see if it is safe and effective for people with moderately to severely active rheumatoid arthritis. The drug likely works by reducing inflammation and pain.

Eligible Conditions
  • Rheumatoid Arthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change From Baseline on the Disease Activity Score Modified to Include the 28 Diarthrodial Joint Count-High-Sensitivity C-Reactive Protein (DAS28-hsCRP)
Secondary study objectives
Change From Baseline for Mean Clinical Disease Activity Index (CDAI)
Change From Baseline for Mean Simplified Disease Activity Index (SDAI)
Change From Baseline in Mental Component Score (MCS), Physical Component Score (PCS) of the Medical Outcomes Study 36-Item Short Form Health Survey Version 2 Acute (SF-36v2 Acute)
+4 more

Side effects data

From 2022 Phase 2 trial • 98 Patients • NCT04634253
8%
Nausea
2%
Osteoarthritis
2%
Pruritus
2%
Nasopharyngitis
2%
Dyslipidaemia
2%
Back pain
2%
Hypothyroidism
2%
Rhinitis
2%
Upper respiratory tract infection
2%
Vomiting
2%
Arthralgia
2%
Covid-19
2%
Hyperglycaemia
2%
Headache
2%
Hypoaesthesia
2%
Pyrexia
2%
Upper respiratory tract infection bacterial
2%
Urinary tract infection
2%
Vulvovaginal candidiasis
2%
Diabetes mellitus
2%
Diarrhoea
2%
Dermatitis atopic
100%
80%
60%
40%
20%
0%
Study treatment Arm
LY3462817 700 mg
Placebo
LY3462817 300 mg

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3462817 700 mgExperimental Treatment1 Intervention
Participants received IV infusion of 700 mg LY3462817 solution.
Group II: LY3462817 300 mgExperimental Treatment1 Intervention
Participants received Intravenous (IV) infusion of 300 mg LY3462817 solution.
Group III: PlaceboPlacebo Group1 Intervention
Participants received IV infusion of 0.9% sodium chloride solution (Placebo).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3462817
2021
Completed Phase 2
~100

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,680 Previous Clinical Trials
3,466,286 Total Patients Enrolled
28 Trials studying Rheumatoid Arthritis
17,080 Patients Enrolled for Rheumatoid Arthritis
Study DirectorEli Lilly and Company
1,391 Previous Clinical Trials
428,743 Total Patients Enrolled
17 Trials studying Rheumatoid Arthritis
13,445 Patients Enrolled for Rheumatoid Arthritis
~20 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top